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Abstract
Background Serum gamma-glutamyltransferase (GGT) has
been introduced as a predictive factor for cardiovascular
disease. In this study, we investigated the association of
serum GGT and premature coronary artery disease (CAD)
in candidates for coronary angiography.
Methods In this cross-sectional study, we enrolled male
subjects aged 45 years and female subjects 55 years who
were candidates for elective coronary angiography due to
typical chest pain or a positive non-invasive test. Baseline
characteristics were recorded for all the participants and
serum levels of blood glucose, lipid profile and GGT were
measured. Patients were divided into CAD and non-CAD
groups based on angiography for further comparisons.
Results From a total of 367 patients (age 45.1 ± 6.1 years,
161 males [43.9%]), 176 (47.9%) patients had premature
CAD. A high level of GGT was significantly associated
with the presence of CAD (p < 0.001). A 10-unit increase
in GGT could strongly predict the presence of premature
coronary artery disease (OR: 13.34, 95% CI: 7.19–24.78;
p < 0.001) after adjustment for confounders. The area under
the receiver operating characteristic curve for GGT was
80.9% (range 76.5–85.3) and the sensitivity and specificity
of GGT at a cut-point of 22.5 IU/l was 80.1% and 70.2%,
respectively. Diagnostic accuracy of GGT was 74.9%. The
positive predictive value and negative predictive value for
GGT was 71.3 and 79.3, respectively.
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Conclusion We observed that GGT levels in patients with
typical chest pain or positive non-invasive tests could pre-
dict the presence of premature CAD in young patients.
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Introduction
Coronary artery disease (CAD) is a complex multifacto-
rial condition that is initiated by an intense inflammatory
response to different forms of injury, leading to endothe-
lial dysfunction in the arterial walls and finally resulting
in accelerated atherosclerosis [1]. Premature CAD, defined
as the presence of coronary artery atherosclerotic lesion in
men 45 years and women 55 years [2] is a growing en-
tity in developing countries such as Iran. At least one of the
four classic cardiovascular risk factors – cigarette smoking,
diabetes, hypertension, and dyslipidaemia – is present in
the majority (almost 90%) of patients with premature CAD
[3]. Some of the cardiovascular risk factors, such as fam-
ily history, smoking, hypertension, and diabetes mellitus [2,
4], have shown to be strong predictors for premature CAD,
while others were not [5]. As coronary angiography remains
the gold standard for the diagnosis of CAD [6], identifica-
tion of patients with premature CAD remains a challenge
until they refer with cardiovascular events. Therefore, ear-
lier prediction of this serious condition can help to reduce
cardiovascular mortality and morbidity. Finding tools to
identify individuals at risk and identification of novel pre-
dictive factors, including biomarkers, could greatly help to
detect this condition in its early phases, [2].
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Elevation of serum gamma-glutamyltransferase (GGT),
an important liver enzyme, mediates the preparation of
amino acid to intracellular glutathione and also has a role in
the degradation of extracellular glutathione [7]. Being the
most important non-protein cellular antioxidant, glutathione
degradation has a pro-oxidant role in various conditions,
such as low-density lipoprotein oxidation [8]. These pro-
vide evidence for the pathological impact of a rise in GGT
on stimulating oxidative processes and on regulating the
antioxidant defence system. Accordingly, it can be postu-
lated that GGT may play a role in the inflammatory process
underlying atherosclerosis. Previous studies have demon-
strated the association of serum GGT with cardiovascular
disease, diabetes, and metabolic syndrome [9–11]; it has
been suggested as a predictive factor for the incidence of
CAD and cardiovascular-related mortality [12, 13]. How-
ever, there are insufficient data regarding the association
of GGT and premature CAD. The aim of this study was
to investigate such an association in patients undergoing
coronary angiography at our tertiary heart centre.
Methods
Study population
In this cross-sectional study, between March 2012 and
September 2013 we enrolled male subjects aged 45 years
and female subjects 55 years who were referred to Tehran
Heart Center for elective coronary angiography due to typ-
ical chest pain or positive non-invasive test results (i. e.
electrocardiogram suggestive of ischaemia, positive ex-
ercise tolerance test, or suspicious myocardial perfusion
scan). Exclusion criteria were malignancy, metabolic syn-
drome, abnormal liver function tests (increased level of
GGT combined with elevated aspartate aminotransferase,
alanine aminotransferase, and bilirubin is due to liver dys-
function and possibly biliary tract involvement, so these
patients were excluded), active hepatic disease, and chronic
renal/hepatic insufficiency. Patients with a history of known
CAD or myocardial infarction, cardiac surgery, and regular
alcohol consumption (more than 90 ml daily for at least
6 months), were excluded from the study.
This study conforms to the principles outlined in the
Declaration of Helsinki. Written informed consent was ob-
tained from the participants before enrolment. The study
protocol was approved by the local Institutional Commit-
tee of Medical Ethics and the Research Board of Tehran
University of Medical Sciences.
Demographic and clinical data
Baseline characteristics, including demographic data and
past medical history, were recorded for all the participants
in a face-to-face interview at the time of admission. A pos-
itive history of hypertension was considered in patients al-
ready taking antihypertensive agents or who had two blood
pressure readings at least five minutes apart in the sit-
ting posture ≥140/90 mm Hg. Dyslipidaemia was consid-
ered in patients taking lipid-lowering agents, total choles-
terol ≥200 mg/dl, or low density lipoprotein ≥130 mg/dl.
Diabetes mellitus was positive in patients with a definite his-
tory of diabetes and treatment with glucose-lowering agents
or a fasting plasma glucose ≥126 mg/dl or two-hour post-
load glucose ≥200 mg/dl.
Laboratory measurements
Venous blood samples were obtained before coronary an-
giography from the antecubital vein at the catheterisation
laboratory of our centre to measure serum biochemistry.
These measurements included fasting blood glucose, lipid
profile (i. e. triglyceride, total cholesterol, low-density
lipoprotein [LDL], and high-density lipoprotein [HDL]),
liver function tests (aspartate aminotransferase, alanine
aminotransferase, and bilirubin) and serum GGT. Serum
GGT was measured using Cobas Integra 400 plus (Roche
Diagnostics, Basel, Switzerland) by enzymatic colorimetric
assay.
Angiography
The presence of premature CAD was evaluated by con-
ventional angiography at the catheterisation laboratory of
Tehran Heart Center under local anaesthesia by an expert
cardiologist. The angiography was performed by the stan-
dard Judkins technique using a quantitative coronary angio-
graphic system. Significant atherosclerotic coronary artery
lesion was defined according to the guideline of the Amer-
ican College of Cardiology/American Heart Association as
a 50% or more narrowing of the lumen diameter in at least
one major coronary artery [14].
All coronary angiograms were evaluated by a qualified
cardiologist unaware of the patient’s biochemical markers
results. The extent of coronary atherosclerosis was assessed
with the clinical vessel score and CAD was defined as the
presence of ≥50% stenosis in the coronary arteries: single-
vessel disease indicated stenosis in the left anterior descend-
ing artery or left circumflex artery or right coronary artery
or a main branch of one of these arteries; double-vessel dis-
ease is stenosis in two coronary arteries other than the left
main artery, and triple-vessel disease refers to stenosis in
three coronary arteries [15]. The study variables were then
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Table 1 Comparing the baseline characteristics of the study groups based on the presence of premature coronary artery disease
Parametersa CAD+ (n = 176) CAD– (n = 191) P-value*
Age, year 45.6 ± 5.6 45.0 ± 6.8 0.53
Male gender, n (%) 85 (48.3) 76 (39.8) 0.1
Diabetes mellitus, n (%) 65 (36.9) 41 (21.5) 0.001
Hypertension, n (%) 88 (50) 73 (38.2) 0.02
Dyslipidaemia, n (%) 85 (48.3) 96 (50.3) 0.70
Smoking, n (%) 57 (32.4) 42 (22) 0.02
Family history of CAD, n (%) 57 (32.4) 56 (29.3) 0.52
Fasting blood sugar, mg/dl 126.9 ± 56.0 110.8 ± 40.2 0.02
Triglyceride, mg/dl 178.8 ± 104.2 168.2 ± 92.3 0.3
Total cholesterol, mg/dl 184.5 ± 58.3 176.3 ± 47.5 0.13
LDL, mg/dl 119.8 ± 45.2 112.4 ± 36.6 0.08
HDL, mg/dl 39.2 ± 10.2 44.5 ± 10.5 <0.001
GGT, IU/l 43.3 ± 12.1 21.46 ± 12.8 <0.001
CAD coronary artery disease, GGT gamma-glutamyl transferase, HDL high density lipoprotein cholesterol, LDL low-density lipoprotein
cholesterol
*p < 0.05 was considered statistically significant
aVariables are shown as mean ± standard deviation or frequency (percentage) where appropriate
compared between the groups with and without significant
CAD. Also, the relationship between serum GGT and the
extent of coronary artery disease based on the vessel score
was examined.
Statistical analysis
Continuous variables were described with mean and stan-
dard deviation (SD) or with median and 25th and 75th per-
centiles for skewed data, and were compared between CAD
and non-CAD groups using the Student’s t or Mann-Whit-
ney U test where appropriate. Categorical variables were
expressed as frequency and percentage and were compared
among groups using the chi-square test. The area under
the receiver operating characteristic (ROC) curve with 95%
confidence interval (CI) was applied to estimate the discrim-
ination power of cardiovascular risk factors and GGT. Vari-
ables which were simultaneously associated with CAD and
GGT with p-values less than 0.2 were considered potential
confounders. A multiple logistic regression model was ap-
plied to evaluate the association of GGT and CAD adjusted
for detected potential confounders. The adjusted effect was
reported through odds ratio (OR) with 95% CI. A Kruskal-
Wallis test was applied to compare GGT among groups of
disease severity. Pairwise comparisons were used to find
different groups in GGT. P-values less than 0.05 were con-
sidered statistically significant. The statistical analysis was
performed using IBM SPSS statistics for windows version
22.0 (Armonk, NY: IBM Corp.).
Results
The mean age of the study participants was 45.1 ± 6.1 years
and 43.9% were men. Based on the coronary angiography
results, from a total of 367 patients 176 (47.9%) had var-
ious degrees of CAD. The frequency of diabetes mellitus,
hypertension and smoking were significantly higher in pa-
tients with premature CAD (p = 0.001, p = 0.02 and p =
0.025, respectively). Levels of fasting blood glucose as well
as GGT were significantly higher in the CAD group (p =
0.024 and p < 0.001, respectively). Only one patient re-
ported one episode of alcohol consumption within the past
6 months. Comparison of the study variables between the
CAD and non-CAD groups is summarised in Table 1.
In the multivariable logistic regression analysis, after
adjustment for gender, diabetes mellitus, hypertension,
smoking, fasting blood glucose, cholesterol, triglyceride
and HDL, a 10-unit elevation in serum GGT was signif-
icantly associated with a twofold increase in the risk of
premature CAD (OR: 2.03, 95% CI: 1.70–2.41.78; p <
0.001).
The area under the ROC curve (AUC), sensitivity, and
specificity of cardiovascular risk factors for detecting pre-
mature CAD in our study population is presented in Table 2.
Serum GGT had the largest AUC for discriminating pre-
mature CAD followed by low HDL and high fasting blood
glucose. Based on the logistic regression model, analysis
was performed for Framingham risk factors (including age,
total cholesterol, HDL, smoking and hypertension) and sig-
nificant premature CAD; findings revealed an AUC of 0.69
for males and 0.71 for females (p < 0.001). Analysis was
repeated after adding GGT to these factors and findings
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Table 2 Receiver operating characteristic (ROC) analysis of cardiovascular risk factor components for discriminating premature coronary artery
disease from normal coronary structure
Risk factor AUC 95% CI Sensitivity Specificity P-value*
Diabetes mellitus 57.7 51.9–63.6 36.9 78.5 0.01
Hypertension 55.9 50.0–61.8 50 61.8 0.05
Smoking 55.2 49.3–61.1 32.4 78 0.08
FBS (cut-point 102.5 mg/dl) 58.40 52.6–64.3 53.40 66.50 0.05
LDL (cut-point 144 mg/dl) 53.4 47.4–59.3 27.8 83.8 0.265
HDL (cut-point 45.5 mg/dl) 64.70 59.1–70.3 45.5 72.70 <0.001
GGT (cut-point 22.5 IU/l) 80.90 76.5–85.3 80.10 70.20 <0.001
AUC area under the ROC curve, FBS fasting blood sugar, GGT gamma-glutamyltransferase, HDL high-density lipoprotein cholesterol
*p < 0.05 was considered statistically significant
Table 3 Diagnostic test indices of Framingham risk factors with and without GGT for predicting premature coronary artery disease in the study
population and men and women separately
Population AUC P-value*
Males Females
Framingham risk factors without GGT 0.69 0.71 <0.001
Framingham risk factors with GGT 0.81 0.86 <0.001
Framingham risk factors: age, total cholesterol, HDL, hypertension, smoking
AUC area under the ROC curve, GGT gamma-glutamyltransferase
*p < 0.05 was considered statistically significant
Fig. 1 The receiver operating characteristic curve for serum GGT used for screening of high-risk CAD patients. a Males (AUC = 77.1%, p <
0.001), b Females (AUC = 83.2%, p < 0.001)
showed the AUC for males to be 0.81 and for females 0.86
(p < 0.001). Based on Table 3 the AUC for GGT alone
is 0.77 for males and 83.2 for females (p < 0.001). So,
although adding GGT to the Framingham risk factors in-
creases their value, GGT has a more important role on its
own (Table 3).
As shown in Fig. 1, the positive and negative predictive
values for GGT were 71.2 (95% CI: 64.4–77.4) and 79.3
(95% CI: 72.4–85.1), respectively. Diagnostic test indices of
GGT as well as cut-off points for predicting premature CAD
in the study population plus men and women separately are
shown in Table 4.
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Table 4 Diagnostic test indices of GGT for predicting premature coronary artery disease in the study population and men and women separately
Population GGT
cut-off
AUC 95% CI Sensitivity Specificity PPV NPV Diagnostic
accuracy
P-value*
All patients 22.5 80.9 76.5–85.3 80.1 70.2 71.3 79.3 74.9 <0.001
Men 35.5 77.1 76.5–85.3 62.4 86.5 82.1 67 73.3 <0.001
Women 22.5 83.2 77.0–88.2 79.1 80 75.8 82.9 79.6 <0.001
AUC area under the ROC curve, CI confidence interval, GGT gamma-glutamyltransferase, NPV negative predictive value, PPV positive predictive
value
*p < 0.05 was considered statistically significant
Fig. 2 Box plot of GGT levels
in the subgroup of patients
based on the presence and extent
of premature CAD as defined
by vessel score (single vessel
disease [SVD] is defined as
stenosis [at least 50%] of LAD,
LCX, RCA or a main branch
of one of them, two-vessel
disease [2VD] is stenosis of
two coronary arteries other than
the left main, and triple-vessel
disease [3VD] is stenosis in three
coronary arteries)
The levels of GGT were also compared between dif-
ferent subgroups of vessel score and we observed that the
level of GGT was significantly lower in normal coronary
individuals (p < 0.001) (Fig. 2). However, the post-hoc pair-
wise comparison revealed that this difference was caused
by low concentrations of GGT in normal coronary patients
and patients with one, two, or three vessel disease did not
statistically differ regarding the GGT levels (p = 0.255).
Discussion
The main finding of the present study was that GGT levels
in the studied patients could predict the presence of prema-
ture CAD with an acceptable precision. We also observed
that GTT was significantly associated with the extent of
premature CAD as measured by the angiographic vessel
score.
Oxidative stress and the resultant endothelial dysfunction
contribute to the micro-vascular complications of metabolic
disease and atherosclerosis [16, 17]. Common risk factors
for atherosclerosis stimulate production of free oxygen rad-
icals, either by endothelial cells or by vascular smooth mus-
cle cells and adventitial cells [18]. Thus, dyslipidaemia, di-
abetes mellitus, hypertension, smoking, advanced age, and
nitrate intolerance all play a part in overproduction of reac-
tive oxygen species [19, 20]. As a result, several processes
involved in atherogenesis will be initiated, including expres-
sion of adhesion molecule, stimulation of vascular smooth
muscle proliferation and migration, endothelial apoptosis,
lipid oxidation, matrix metalloproteinase activation, and al-
teration in vasomotor activity [21, 22]. Already a biomarker
for hepatobiliary disease and alcohol abuse [7], serum GGT
activity has been introduced as a biomarker for oxidative
stress with an apparent association with increased risk of
hypertension, diabetes mellitus, and cardiovascular events
[23, 24]. It also intermediates LDL oxidation through glu-
tathione/GGT-dependent iron reduction process as a part of
atherosclerosis pathogenesis [8]. Moreover, GGT has been
shown to be a valid predictor for cardiovascular mortality
and survival in patients with cardiovascular disease. There-
fore, one can conclude that GGT has tight bonds with car-
diovascular conditions, particularly in early stages of coro-
nary atherosclerosis [13].
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As coronary angiography is an invasive test for the detec-
tion of CAD, GGT can play an invaluable role in predicting
the presence of premature CAD in the young adults who
present with ischaemic symptoms. Presence of the classic
cardiovascular risk factors can predict the presence of CAD
to some degree; however, addition of GGT can increase the
predictive strength. The comparison between the predictors
of CAD in the present study showed that GGT can predict
the presence of premature CAD with a high precision as
compared with other risk factors. This finding is in line with
the result of a similar study that also suggested GGT as an
adjuvant marker for risk assessment of premature CAD and
a screening tool for the candidates of coronary angiography
[25]. The cut-point for GGT in the abovementioned study
is similar to the cut-point for the male patients in our study
as the number of female patients in that study was very low.
Therefore, we suggest the use of serum GGT measurement
as a non-invasive tool for predicting premature CAD in the
young adults who present with ischaemic symptoms.
Study limitations
The advantage of our study is that we provided the cut-
points of GGT for both men and women. However, the
main limitation of this study is its design; this was a single-
centre study performed in a tertiary university hospital and
this may influence our findings due to demographic and
socioeconomic reasons.
Conclusion
Our results showed that GGT, as a cost-effective and quick
test, could predict the presence of premature CAD with
a diagnostic accuracy of 74.9% in our patients. Although
further studies are required to find out the definite cut-off
values for GGT in different populations, the association of
GGT with premature CAD suggests that it can be used as
an adjuvant marker for risk assessment of young patients
who present with ischaemic symptoms and are suspected
to have premature CAD.
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